All In Biotech

Drug Trial Radar · NCT03404791

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Nov 20, 2017

Primary completion

Dec 23, 2019

Study completion Sep 15, 2022

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.

Conditions

  • Urinary Bladder Neoplasms

Interventions

  • TAR-200Drug

    TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: Up to Day 84

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • North Georgia Urology Center

    Dalton, Georgia

  • Chesapeake Urology Research Associates

    Hanover, Maryland

  • Michigan Institute of Urology

    Troy, Michigan

  • University of Rochester

    Rochester, New York

  • Urology Associates, PC

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • North Austin Urology

    Austin, Texas

  • Urology of Virginia, PLCC

    Virginia Beach, Virginia

  • Fund. Puigvert

    Barcelona, Spain

  • Hosp. Univ. 12 de Octubre

    Madrid, Spain

  • Inst. Valenciano de Oncologia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.